Skip to main content

Turmeric prices may recover by year-end, could go above Rs 6,100

The NCDEX October contract has immediate strong support at Rs 5,700 per quintal.

Futures have shown appreciated by more than 10 percent over last month. As the unlocking of nation's economy started, household consumption picked up and similar trend was noticed in medicinal industry as well as exports. So it can be inferred that local as well as overseas demand for turmeric has started improving.

Due to efforts of Agriculture Ministry and increasing awareness about spices being a strong immunity builder, especially turmeric, number of Indians preferring increased consumption of turmeric has improved in last few months.

Out of the estimated total production of 9,38,955 tonnes in 2019-20, annual exports till December 2019 stood at 1,01,500 tonnes as per trade sources. India is the world's largest supplier of turmeric contributing nearly 70-75 percent of global production. As the perception of turmeric being an immunity-boosting product increases, domestic and export demand has started improving.



Exporters have reported that overseas purchases have been increasing for Indian turmeric since April in retail chains in the UK, Germany and Holland. Interesting to note, the entire spices basket has fetched good returns for the country in June. Sowing prospects have reduced as markets had moved in a moderate price band of Rs 500-7,000 per quintal since last 3 years.

There are reports of farmers likely to shift some of the turmeric cultivated areas towards planting of soybean/maize/cotton etc. Therefore sowing prospects are lower for the coming season, indicating drop in production outlook.

All in all, growing demand prospects – export as well as domestic, ongoing festive season, cheaper prices and lower sowing possibilities shall keep price outlook positive for coming month. Most of the inventory is with farmers and they are willing to sell only after noticeable price appreciation.

The NCDEX October contract has immediate strong support at Rs 5,700 per quintal. Immediate Resistance is at Rs 6,120. Closing above that could lead to levels of Rs 6,700-6,900 till October-end.

(The author is VP - Retail Research at Religare Broking Ltd.)

Source – Moneycontro.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more